Evidence map›Paper›PMID 30652694›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Gamma-Secretase Inhibitor, DAPT, Prevents the Development of Retinopathy of Prematurity in a Rat Model by Regulating the Delta-Like Ligand 4/Notch Homolog-1 (DLL4/Notch-1) Pathway.

Wei Sun, Jing Li, Yinan Li, Jiao Zheng, Xiaoming Zhang, Xuelin Huang, Shujun Li

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. [Advances in pharmacological research for retinopathy of prematurity].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wei SunDepartment of Ophthalmology, Guangdong Women and Childrens' Hospital, Guangzhou, Guangdong, China (mainland).
Jing LiDepartment of Ophthalmology, Guangdong Women and Childrens' Hospital, Guangzhou, Guangdong, China (mainland).
Yinan LiDepartment of Anesthesiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (mainland).
Jiao ZhengDepartment of Ophthalmology, Guangdong Women and Childrens' Hospital, Guangzhou, Guangdong, China (mainland).
Xiaoming ZhangDepartment of Ophthalmology, Guangdong Women and Childrens' Hospital, Guangzhou, Guangdong, China (mainland).
Xuelin HuangDepartment of Ophthalmology, Guangdong Women and Childrens' Hospital, Guangzhou, Guangdong, China (mainland).
Shujun LiDepartment of Oncology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China (mainland).
Guangdong Province Women and Children Hospital · CNGuangdong Medical College · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Retinopathy of prematurity (ROP), or retrolental fibroplasia, affects premature infants who have undergone intensive care with oxygen therapy. This study aimed to investigate the inhibitory effect of the gamma-secretase inhibitor, DAPT, on neovascularization and its mechanism in a rat model of ROP. MATERIAL AND METHODS Sixty neonatal Sprague-Dawley (SD) rats included the control group (n=20), the model group (n=20), and the DAPT-treated group (n=20). The rat model of ROP was established using repeat cycles of oxygen inhalation. Enzyme-linked immunosorbent assay (ELISA) measured serum levels of vascular endothelial growth factor (VEGF), VEGF receptor-1 (VEGFR-1), and VEGFR-2. Histology of the retinal tissue included immunohistochemistry for the expression of Notch homolog-1 (Notch-1) and delta-like ligand 4 (DLL4). Retinal mRNA levels of DLL4, Notch-1, VEGF, VEGFR-1, and VEGFR-2 were evaluated with quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS The rat model of ROP showed increased serum levels of VEGF, VEGFR-1, and VEGFR-2 compared with the control group, which were decreased in the DAPT group. Histology of the retinal tissue in the model group showed degeneration of the retinal ganglion cells, and immunohistochemistry showed increased expression of Notch-1 and DLL4 compared with the control group and DAPT group. Retinal tissue in the model group had increased mRNA levels of DLL4, Notch-1, VEGF, VEGFR-1, and VEGFR-2 compared with the control group, and the DAPT group. CONCLUSIONS In a rat model, treatment with DAPT reduced the retinal changes associated with ROP with a mechanism that involved VEGF and its receptors through the DLL4/Notch-1 pathway.

Indexed as

Amyloid Precursor Protein SecretasesAnimalsAnimals, NewbornDipeptidesDisease Models, AnimalIntracellular Signaling Peptides and ProteinsMaleMembrane ProteinsNeovascularization, PathologicRatsRats, Sprague-DawleyReceptor, Notch1Retinopathy of PrematuritySignal TransductionVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Amyloid Precursor Protein Secretasesdelta proteinDipeptidesIntracellular Signaling Peptides and ProteinsMembrane ProteinsN-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl esterReceptor, Notch1Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2

Identifiers

PMID30652694
PMCPMC6345111
OpenAlexW2911121166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.